Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being done to find out why some people with mucus dripping down the back of their throat have a nagging cough while others do not cough.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

NCT04256733

Cough

COMPLETED EARLY_PHASE1

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257

Nonallergic Irritant Rhinitis

COMPLETED PHASE2

Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.

NCT01223820

Idiopathic Rhinitis Patients Healthy Controls

COMPLETED PHASE4

The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device

NCT02079792

Sinusitis

COMPLETED PHASE4

Comparison of Cold Dry Air Exposure, Discs and Capsaicin

NCT02334605

Nasal Hyper Reactivity

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the protocol is to determine the pathogenesis of cough in diseases of the aerodigestive tract. There were over 24 million ambulatory chronic cough visits nationally in 1991 and over 8,000 visits in 2004 at MCR. Current guidelines for chronic cough are based on case series and on empirical expert opinions. Studies have implicated mucosal inflammation, heightened sensitivity of capsaicin cough receptors on peripheral nerves and elaboration of inflammatory mediators including tussigenic neuropeptides. There are gaps in our knowledge of what triggers cough in many disease states. For example, postnasal drip syndrome has been estimated to account for 70% of chronic cough, yet it is known that not all patients with postnasal drip have chronic cough. Our hypothesis is that there must be critical factor/s that cause cough in one patient with postnasal drip but not in another. This study will evaluate whether there exists differences in capsaicin cough sensitivity, neuropeptides levels and mucosal inflammation in patients with postnasal drip and chronic cough and compared to its natural control group, subjects with postnasal drip with and without chronic cough. After standard therapy to eliminate postnasal drip, repeat measurement of capsaicin sensitivity and nitric oxide levels will be obtained. There is a critical need to determine the mechanisms underlying cough for better management. The study results will provide insight and fill gaps in our knowledge and will serve to advance future work evaluating mechanisms of cough in other disease states including asthma, GERD, interstitial lung disease and smokers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Nasal Drip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Post Nasal Drip and chronic cough

No interventions assigned to this group

2

Post nasal drip and no cough

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Postnasal Drip with chronic cough:

1. Postnasal drip by rhinoscopy
2. Cough by visual analog scale.
3. Patients have to be 18 years old or older.
4. Cough-variant asthma must be excluded by a negative methacholine challenge test within one year, or documented failure of chronic cough to resolve after administration of inhaled corticosteroid (\> one-month duration). Asthma is defined by the ATS guidelines.
5. Subjects must have a negative chest radiogram or Chest CT scan within 6 months.
6. No active GERD symptoms (\< 7 RSI score) \& a stable dose of Proton Pump Inhibitor (4 weeks).

Eligibility Criteria of Postnasal Drip without cough:
7. Postnasal drip by rhinoscopy
8. No cough by visual analog scale.
9. Patients have to be 18 years old or older.

Exclusion Criteria

1. Presence of nasal polyposis and/or sinusitis or active GERD symptoms on examination.
2. Current smokers (smoking within the 2 months prior to the study) will be excluded.
3. Patients with an upper respiratory tract infection within the preceding 8 weeks.
4. Patients taking angiotensin converting enzyme inhibitors.
5. Patients on leukotriene receptor antagonist and/ or nasal topical corticosteroids or inhaled corticosteroids. Patient must be off nasal or inhaled corticosteroid by at least 4 weeks.

1. A chest radiogram is not necessary in this group.
2. Patients taking leukotriene inhibitors, or using nasal steroid therapy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No